BriaCell's Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients, Topline Data Expected 2026
BCTX sits 16% above its 52-week low of $3.6.
Summary
BriaCell Therapeutics announced that its pivotal Phase 3 Bria-ABC study, evaluating Bria-IMT for advanced breast cancer, has screened over 315 and enrolled over 230 patients. This significant enrollment milestone is a positive development for the clinical-stage biotech, especially following its recent 10-Q filing (March 10, 2026) which included a going concern warning and substantial net losses. The study's inclusion in Nature Medicine's list of trials to watch in 2026 and its FDA Fast Track designation further underscore its importance. For a micro-cap company, progress in a Phase 3 trial is a material de-risking event and a strong positive catalyst, potentially improving the company's long-term prospects. Investors will now closely watch for the anticipated interim analysis and topline data readout, both expected in 2026.
At the time of this announcement, BCTX was trading at $4.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.2M. The 52-week trading range was $3.60 to $37.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.